Key Takeaway: NRx Pharmaceuticals is developing two treatments, NRX-101 and NRX-100, aimed at addressing bipolar depression and acute suicidal crises. NRX-101 combines D-cycloserine and lurasidone, demonstrating greater efficacy in reducing suicidality compared to lurasidone alone. NRX-100 is an IV ketamine formulation designed for acute treatment in depression.
Price reaction · baseline $1.83 (2024-08-29 close) · hit after-hours · 1 other NRXP headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
POSITIVE FACTORS
NRX-101 shows higher efficacy than lurasidone alone.
NRX-100 is a novel treatment for acute suicidal crises.
Both treatments target serious mental health issues.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Full Press Release Details
Published by Afamefuna Onyeogulu | August 29, 2024
What Are NRX-101 and NRX-100?
It’s against this backdrop that NRx Pharmaceuticals sought to develop two new pharmacological treatments for bipolar depression with a risk of suicide.
• NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality.
• NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression.
– read full article –
Frequently Asked Questions
What is NRX-101?
NRX-101 is a combination of D-cycloserine and lurasidone for treating suicidal treatment-resistant bipolar depression.
How does NRX-100 work?
NRX-100 is a preservative-free IV ketamine formulation studied for acute suicidal crises in depression.
What conditions do these treatments target?
Both NRX-101 and NRX-100 target bipolar depression and acute suicidal crises.
What is the efficacy of NRX-101?
NRX-101 has shown higher efficacy in reducing akathisia and suicidality compared to lurasidone alone.